Please remember all of this is for informational purposes only. We hope you found some useful information. Thanks for visiting the Maryland Injury Lawyer Blog. If you or a loved one has had any of these complications, contact our product liability lawyers at 1.800.553.8082, or send us some information online for a free consultation. Our lawyers are investigating problems with the Medtronic Infuse Bone Graft, including death, inflammation/swelling, breathing problems, nerve damage, sterility, and cancer. Because there is no centralization of cases, it is difficult to know how many there are. Importantly the time to file a claim varies based on state law, so patients who suffer from Infuse Bone Graft injuries should contact a lawyer as soon as possible. There is no class action for these devices, so each case will stand on its own for now. These employees allege that Medtronic gave incentives (bribes) to use Infuse. A whistleblower lawsuit is spearheaded by company employees, usually with the assistance of a law firm or the Department of Justice. There have been several whistleblower lawsuits filed against Medtronic. The 2012 sales of Infuse dropped by about 18 percent, primarily due to an eye-opening June 2011 study in The Spine Journal. But these are the facts and they are not in any real dispute. This sounds like some wild and wacky plaintiffs’ lawyer’s wild conspiracy. There was a 2012 investigation by the Senate Committee on Finance which determined that Medtronic made payments of at least $210 million, paid in exchange for favorable data that did much to convince the FDA to approve Infuse. Other payments occurred in at least 13 sponsored studies. It looks like the company was paying for guaranteed results of scientific research. This looks like a major conflict of interest. That surgeon was instrumental in an Infuse Bone Graft study. Medtronic admitted to paying one surgeon around $800,000 in connection with Infuse. The desire for profits from Medtronic and doctors’ passionate desire to make more money on the side helped get us into this mess. But to understand what happened here, you really have to follow the money. The cliché “follow the money” is so tired and played. That is not a use studied or approved by the FDA, and it is highly illegal (not to mention dangerous) for a company to encourage doctors to use products for unapproved uses. Further Medtronic encouraged off-label use, promoting it for neck procedures. Of most concern is that Medtronic’s internal product testing had 50 times fewer complications than a separate post-market study. To be generous, Medtronic appears to have cut corners with this product. difficulty breathing or swallowing (for neck surgeries).This product has a lot going against it, including: But patients have had a lot of problems and complications. The purpose of the Infuse is to grow bone using a complicated recombinant human bone morphogenetic protein (rhBMP-2) in a few approved areas, including dental procedures, tibia fractures, and degenerative disc disease. The cases would have been worth billions but the Supreme Court completely bailed them out with an awful preemption ruling. Most prolifically in recent years was the way they botched their defibrillator leads. Medtronic is a company that, in my opinion, has a history of taking shortcuts that hurt patients. Bone grafts, as cool as they are, have to be done right, or the cure will be worse than the original problem. But it is worth nothing that most of these companies have changed the world and decreased human suffering. Admittedly, I just focus on the negative. Most of these companies are doing great work. Drug and medical device companies come up with some unbelievable stuff that have really changed the world. MARKET ANALYSIS, TRENDS, AND FORECASTS, MAY 2ġ.We have the technology to essentially create bone. The report profiles 42 companies including many key and niche players such as: Company profiles are primarily based on public domain information including company URLs. Market data and analytics are derived from primary and secondary research. Also, a five-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World.Īnnual estimates and forecasts are provided for the period 2016 through 2024. The US market is additionally analyzed by the following Segments: Demineralized Bone Matrix, Bone Morphogenetic Protein, Stem Cell Based Bone Grafts, and Synthetic Bone Grafts. This report analyzes the worldwide markets for Bone Graft Substitutes in US$ Million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |